UY29127A1 - Nuevos derivados de pirimidina y su uso - Google Patents

Nuevos derivados de pirimidina y su uso

Info

Publication number
UY29127A1
UY29127A1 UY29127A UY29127A UY29127A1 UY 29127 A1 UY29127 A1 UY 29127A1 UY 29127 A UY29127 A UY 29127A UY 29127 A UY29127 A UY 29127A UY 29127 A1 UY29127 A1 UY 29127A1
Authority
UY
Uruguay
Prior art keywords
pyrimidine
treatment
new derivatives
diseases
prophylaxis
Prior art date
Application number
UY29127A
Other languages
English (en)
Inventor
Dr Hilmar Bischoff
Dr Axel Kretschmer
Dr Klemens Lustig
Dr Elke Dittrich-Wengenroth
Dieter Lang
Dr Marcus Bauser
Lars Barfacker
Dr Ulrich Rosentreter
Dr Peter Ellinghaus
Claudia Hirt-Dietrich
Martin Raabe
Christian Pilger
Stephan Bartel
Armin Kern
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of UY29127A1 publication Critical patent/UY29127A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención se refiere a nuevos derivados de pirimidina, a procedimientos para su preparación, a su uso para el tratamiento y/o la profilaxis de enfermedades, así como a su uso para la preparación de medicamentos para el tratamiento y/o la profilaxis de enfermedades, preferentemente para el tratamiento y/o la prevención de enfermedades cardiovasculares, en particular, dislipidemias, arteriosclerosis, insuficiencia cardíaca, trombosis y síndrome metabólico.
UY29127A 2004-09-25 2005-09-23 Nuevos derivados de pirimidina y su uso UY29127A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004046623A DE102004046623A1 (de) 2004-09-25 2004-09-25 Neue Pyrimidin-Derivate und ihre Verwendung

Publications (1)

Publication Number Publication Date
UY29127A1 true UY29127A1 (es) 2006-04-28

Family

ID=35063041

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29127A UY29127A1 (es) 2004-09-25 2005-09-23 Nuevos derivados de pirimidina y su uso

Country Status (22)

Country Link
US (1) US20080261990A1 (es)
EP (1) EP1797045A1 (es)
JP (1) JP2008514559A (es)
KR (1) KR20070055621A (es)
CN (1) CN101065364A (es)
AR (1) AR051295A1 (es)
AU (1) AU2005287589A1 (es)
BR (1) BRPI0517327A (es)
CA (1) CA2582492A1 (es)
DE (1) DE102004046623A1 (es)
EC (1) ECSP077340A (es)
GT (1) GT200500266A (es)
IL (1) IL182136A0 (es)
MA (1) MA28882B1 (es)
MX (1) MX2007003428A (es)
NO (1) NO20072051L (es)
PE (1) PE20060657A1 (es)
RU (1) RU2007115215A (es)
SV (1) SV2007002235A (es)
TW (1) TW200628451A (es)
UY (1) UY29127A1 (es)
WO (1) WO2006032384A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080254036A1 (en) * 2007-04-13 2008-10-16 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
KR100813387B1 (ko) * 2007-06-26 2008-03-12 신명곤 부형제 첨가없이 인삼농축액으로 유동성 및 저장성이우수한 인삼농축액환 제조 방법
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
US20130197043A1 (en) 2010-08-31 2013-08-01 Snu R&Db Foundation Use of the fetal reprogramming of a ppar agonist
JP6217938B2 (ja) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
US20130108573A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
CN103130732A (zh) * 2011-11-22 2013-06-05 上海博康精细化工有限公司 3,5-二甲基-4-氯甲基异噁唑的制备方法
EP2968262A1 (en) 2013-03-15 2016-01-20 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
CA2907230A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
WO2017190050A1 (en) * 2016-04-28 2017-11-02 Cornell University Inhibitors of soluble adenylyl cyclase
AU2020221834A1 (en) 2019-02-12 2021-09-02 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency
CN115598267B (zh) * 2022-12-13 2023-05-09 山东省食品药品检验研究院 一种格列齐特中潜在遗传毒性杂质的分析方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4598278B2 (ja) * 1999-04-28 2010-12-15 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｐｐａｒ受容体リガンドとしてのジアリール酸誘導体
GB0214254D0 (en) * 2002-06-20 2002-07-31 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
CN101065364A (zh) 2007-10-31
ECSP077340A (es) 2007-04-26
RU2007115215A (ru) 2008-11-10
MA28882B1 (fr) 2007-09-03
KR20070055621A (ko) 2007-05-30
AR051295A1 (es) 2007-01-03
CA2582492A1 (en) 2006-03-30
JP2008514559A (ja) 2008-05-08
GT200500266A (es) 2006-05-11
TW200628451A (en) 2006-08-16
EP1797045A1 (de) 2007-06-20
US20080261990A1 (en) 2008-10-23
MX2007003428A (es) 2008-03-13
DE102004046623A1 (de) 2006-03-30
NO20072051L (no) 2007-06-07
BRPI0517327A (pt) 2008-10-07
WO2006032384A1 (de) 2006-03-30
PE20060657A1 (es) 2006-08-12
SV2007002235A (es) 2007-03-20
AU2005287589A1 (en) 2006-03-30
IL182136A0 (en) 2007-07-24

Similar Documents

Publication Publication Date Title
UY29127A1 (es) Nuevos derivados de pirimidina y su uso
ECSP077357A (es) Procedimiento para la preparación de 4-{4-[cloro-3-(trifluorometil) fenil] amino}carbonil)amino]fenoxi}n-metilpiridina-2-carboxamida
DOP2006000062A (es) Derivados de acido pirimidincarboxilico y su uso
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
AR058098A1 (es) Derivados de acidos dicarboxilicos y su uso
CR20110485A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
ECSP055524A (es) Derivados de indolin-fenilsufonamida
UY31228A1 (es) Ariloxazoles sustituidos y su uso
UY31484A1 (es) Piperidinas heteroaril-sustituidas
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
ECSP088569A (es) Nuevos derivados de furopirimidina acíclicos sustituidos y uso de los mismos para el tratamiento de enfermedades cardiovasculares
ECSP11011483A (es) Piperidinas sustituidas
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
UY30582A1 (es) Derivados de acido 2-fenoxinicotinico y su uso
CR20110627A (es) Piperidinas sustituidas
UY28115A1 (es) Derivados del acido isoftalico
WO2011141113A3 (de) Kombination aus vitamin k und nikotinamid
DOP2005000177A (es) Nuevos derivados de pirimidina y su uso
EA200970293A1 (ru) Новые производные 5-тиоксилопиранозы
EA200970292A1 (ru) Производные 5-тиоксилопиранозы и их применение в терапии
DOP2005000174A (es) Fenilaminotiazoles sustituidos y su uso
DOP2003000663A (es) Derivados de indolinfenilsulfonamida
HN2008000946A (es) Nuevos derivados de furopirimidina aciclicos sustituidos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160530